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Nuclear accidents and terrorism present a serious threat for mass casualty. Accidental or intended radiation exposure leads to 
radiation-induced gastrointestinal (GI) syndrome. However, currently there are no approved medical countermeasures for GI 
syndrome. Thus, developing novel treatments for GI syndrome is urgent. Mesenchymal stem cells (MSCs) derived from bone 
marrow are a subset of multipotent adult somatic stem cells that have the ability to undergo self-renewal, proliferation and plu-
ripotent differentiation. MSCs have advantages over other stem cells; they can be easily isolated from patients or donors, read-
ily expanded ex vivo, and they possess reparative and immunomodulatory properties. Moreover, MSCs have been shown to be 
powerful tools in gene therapy and can be effectively transduced with vectors containing therapeutic genes. Therefore, the 
therapeutic potential of MSCs has been brought into the spotlight for the clinical treatment of GI syndrome. In this review, we 
discuss the possible role of MSCs in radiation-induced GI syndrome. 
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Accidental or intended radiation exposure in a mass casual-
ty setting presents a serious and ongoing threat. Exposure to 
ionizing radiation not only causes apoptosis of intestinal 
crypt cells and functional changes, but also results in a 
complex interplay of pathophysiological processes. These 
deleterious effects, including inflammatory responses, diar-
rhea, hematochezia, and malabsorption, are seen clinically 
as radiation-induced gastrointestinal (GI) syndrome [13]. 
The acute phase symptoms of GI syndrome may persist for 
a short time, but long-term complications can represent sig-
nificant clinical conditions with high morbidity. However, 
the treatments usually applied to manage GI syndrome are 
only symptomatic [4]. Therefore, developing novel and ef-
fective therapeutics for radiation-induced GI syndrome is 
necessary and important. Mesenchymal stem cells (MSCs) 
are non-hematopoietic stem cells, first isolated from bone 
marrow, with subsequent isolation from other adult tissues. 
They exhibit the capacity for self-renewal, proliferation and 
differentiation into various cells under appropriate stimuli. 
MSCs are capable of self-replication and multi-lineage dif-
ferentiation [5,6]. Stem cell-based approaches using MSCs 
are promising for the development of GI syndrome therapy. 
The aim of this review article is to illustrate the potential of 
MSCs in the treatment of GI syndrome. 
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1  Overview of GI syndrome 
More than 60% of patients with abdominal or pelvic tumors 
might receive radiotherapy. However, GI syndrome is a 
major limiting factor in abdominal and pelvic radiotherapy. 
GI syndrome occurs in more than 10%20% of patients 
who have undergone abdominopelvic radiotherapy. GI epi-
thelial cells are one of the most radiosensitive cell types, 
especially intestinal epithelial stem cells. Ionizing irradia-
tion induces cellular, tissue and organ toxicity. The genera-
tion of reactive oxygen species (ROS) not only contributes 
to apoptosis and functional changes of intestinal crypt cells, 
but also results in a complex interplay of pathophysiological 
processes [7]. Currently, there are no approved medical 
countermeasures to alleviate GI syndrome. Several studies 
have shown that cytokines such as interleukin 11 (IL-11), 
granulocyte colony-stimulating factor (G-CSF) and basic 
fibroblast growth factor (b-FGF) could inhibit apoptosis of 
intestinal epithelial cells and impair radiation-induced intes-
tinal damage [8,9]. However, cytokine treatment is not ef-
fective against higher doses of radiation-induced tissue in-
jury. Therefore, interventions that reduce intestinal radiation 
injury are urgently needed. 
2  The pathogenesis of GI syndrome  
The pathogenesis of radiation-induced GI syndrome re-
mains underdeveloped [10]. The GI tract is particularly ra-
diosensitive. Exposure to ionizing radiation kills crypt stem 
cells or villus endothelial cells. Destructive changes of the 
GI epithelial cells cause breakdown of the mucosal barrier, 
resulting in severe secretory diarrhea, dehydration and flu-
id-electrolyte imbalance, leading to prominent features in-
cluding vascular damage, smooth muscle degeneration and 
intestinal wall fibrosis [11,12]. Ionizing radiation initiates 
inflammation by the production of ROS and induces dou-
ble-strand breaks in DNA, mucosal breakdown, or necrosis 
[13]. Several molecular pathways have been implicated in 
regulating radiation-induced apoptosis in crypt cells, in-
cluding those of the tumor suppressors, p53 and Ataxia tel-
angiectasia-mutated (ATM) P53, which have been suggest-
ed to play a key role in determining the fate of cells that 
have potentially received DNA damage. P53 transactivates 
p21, which results in delayed progression during S-phase of 
the cell cycle. This is considered to be one of the main 
mechanisms of G1-phase arrest in crypt precursor cells [14]. 
Knocking out pro-apoptotic genes, Bax or Bak, results in 
apoptosis of vascular endothelial cells of the GI tract, fol-
lowing intestinal radiation injury in mice [15]. Others be-
lieved that endothelial apoptosis, independent of p53, is 
involved in the pathogenesis of GI syndrome, and suggest 
that radiation-targeted cells switch from endothelial cells to 
epithelial cells at higher doses of radiation [16]. Acid 
sphingomyelinase (ASMase)-mediated ceramide production 
is suggested to be responsible for apoptosis, in both endo-
thelial cells and epithelial cells. b-FGF promotes stem cell 
renewal, progenitor cell differentiation and epithelial cell 
proliferation. Systemic administration of b-FGF is capable 
of suppressing ASMase in endothelial cells, which in turn 
was found to protect the murine small intestine from radia-
tion-induced damage [17,18]. Zhang et al. [17] have shown 
that survival of crypt epithelial cells is significantly in-
creased and apoptosis of endothelial cells pharmacological-
ly inhibited in mice by intravenous injection of b-FGF prior 
to irradiation. Endothelial dysfunction likely plays a key 
role in both early and delayed radiation responses in the 
intestine. Radiation induces alterations in expression of the 
apoptosis-related proteins, C-fos, Jas/Fasl and P53, which 
eventually results in endogenous damage and delayed en-
dogenous intestinal epithelial apoptosis. P53-activation also 
leads to cell cycle arrest and DNA double-strand break re-
pair, or apoptosis. Caspase-3 may play an important role in 
the physiological process of apoptosis, which involves acti-
vation of caspases, constitutively expressed in most cells of 
the crypt and villus [19]. The BH3-only members of the 
Bcl-2 protein family and p53 up-regulate modulator of 
apoptosis (PUMA) are expressed at the early stage of apop-
tosis. PUMA has been shown by multiple research groups to 
play an essential role in both P53-dependent and 
P53-independent apoptosis of intestinal stem cells (ISCs) 
[20]. P53 levels increase within minutes of DNA damage, 
as well as PUMA, NOXA and other members of the bck-2 
family [21]. Upon transcriptional induction in response to 
radiation-induced DNA damage, PUMA functions through 
other Bcl-2 family members, including Bax, Bcl-2 and 
Bcl-xL, to induce mitochondrial dysfunction and caspase 
activation. Qiu and colleagues [22] have shown that 
PUMA-deficient mice exhibit blocked crypt apoptosis fol-
lowing radiation, and that suppressing PUMA leads to ra-
dio-protection and prolonged survival in ISCs. 
P53-mediated growth arrest following DNA damage occurs 
in ISCs. It therefore appears that regulation of P53 activity 
in ISCs has emerged as a key concept in the injury response 
of these progenitor cells. The nuclear factor κB (NF-κB) 
signaling pathway may also be involved in GI syndrome 
injury [23]. As well as deepening understanding of the 
pathogenesis mechanisms of GI syndrome, it is possible to 
open up new perspectives for the treatment of GI syndrome. 
3  Biological characteristics of MSCs 
Bone marrow-derived MSCs are a heterogeneous subpopu-
lation of non-hematopoietic stem cells. There is no single 
surface marker specific for MSCs. Generally, MSCs derived 
from standard cultures have been defined by their homoge-
neous expression of surface markers, such as CD29, CD44, 
CD90, CD73 and CD105, and lack in expression of CD34, 
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CD45, CD14, B7-1, B7-2 and HLA-DR [24]. MSCs have 
been shown to be able to differentiate into various cell line-
ages, including osteoblasts, adipocytes, chondrocytes, my-
oblasts and fibroblasts [25,26], as well as cells of the GI 
epithelial, liver, skin, lung, pancreas and nerve lineage 
[27–29]. 
In addition to the aforementioned characteristics, MSCs 
have advantages over other stem cells, in that they can be 
easily isolated from patients or donors and efficiently 
gene-engineered. In the past few years, the use of MSCs in 
gene therapy has gained momentum. Many reports have 
shown that MSCs were useful as vehicles for cell and gene 
therapy. The strategies for gene delivery into MSCs include 
using viral vectors, non-vectors and three-dimensional/  
reverse transfection systems. The resulting expression of 
exogenous genes in transfected MSCs enhances tissue spec-
ificity. Overexpression of chemokine receptor 1 (CCR1), 
the receptor for CCL7, or chemokine receptor 2 (CXCR2), 
the receptor for both CXCL1 and CXCL2, enhances the 
migration, survival and engraftment of MSCs, and may 
provide a new therapeutic strategy for the injured myocar-
dium [30]. MSCs can serve as cellular vehicles for gene 
delivery and are being developed to treat various diseases. 
Previous studies report that MSCs accelerate epithelial re-
newal and absorptive functions of the intestine in GI syn-
drome by reducing the level of proinflammatory cytokines, 
while secreting factors that support the regeneration of ISCs 
and their niche [30,31]. Thus, stem cell therapy using MSCs 
may be a very attractive option for treatment of GI syn-
drome.  
4  Therapeutic potential of MSCs in GI syn-
drome 
MSCs are promising for the development of future therapies, 
based on their capacity to differentiate into multi-lineage 
cell types and also act as bioreactors of soluble factors to 
promote tissue regeneration at the injured sites. Several 
studies demonstrate that MSCs migrate to sites of local tis-
sue damage or inflammation. For example, Kudo et al. [32] 
provide evidence that injection of MSCs into the wall of the 
irradiated (30 Gy) intestine of mice immediately improves 
survival rates and recovery of the intestinal injury. Sémont 
et al. [33] report that infusion of MSCs prolongs the 
lifespan of mice and improves the renewal capability of the 
small intestinal epithelium and small intestinal structure. 
Total body irradiation (TBI) has been shown to enhance 
MSC transplantation in the bone marrow and muscle, lead-
ing to further engraftment in the bone marrow, brain, heart, 
lung, liver and intestine [34,35]. Local irradiation in addi-
tion to TBI increases homing of injected cells to the injured 
tissues and to other tissues outside the local irradiation field 
[36]. Our group has previously shown that human MSCs 
delivered to NOD/SCID mice with GI syndrome via the 
intravenous route were distributed within the GI tract and 
proliferated in vivo [37]. 
However, it is important to note that the engraftment rate 
of MSCs in the intestinal mucosa is generally low, ranging 
from 0.17%2.7% [38]. Thus, rarity of cell engraftment is 
the key problem that hampers the practical application of 
MSCs to GI syndrome, and more efforts should be focused 
on enhancing levels of engraftment. The stromal cell-   
derived factor-1 (SDF-1)/CXC receptor 4 (CXCR4) axis 
plays an essential role in mobilization and engraftment of 
stem cells [39,40]. SDF-1 is a homeostatic chemokine. The 
increase in inflammatory chemokine concentration of 
SDF-1 at the site of inflammation is a crucial mediator in 
trafficking of MSCs to the site of tissue damage, such as 
after heart infarct, ischemia, irradiation and toxic liver 
damage [41]. It is well known that MSCs express the spe-
cific SDF-1 chemokine receptor, CXCR4, and migrate to 
injured sites by SDF-1/CXCR4 axis. Many groups have 
attempted to modify the functional properties of MSCs to 
increase their homing potential. Overexpression of CXCR4 
with retroviral vector significantly enhanced the engraft-
ment rate of MSCs into enteric mucosa, and the implanted 
MSCs effectively ameliorated radiation-induced intestinal 
injury [42]. Although the SDF-1/CXCR4 axis has been well 
characterized as a pathway for MSC homing, several other 
ligand-receptor interactions have also recently been shown 
to be involved in MSC homing [43]. Sasaki et al. [44] re-
cently demonstrated that infused-MSCs significantly con-
tribute to wound repair via MSC accumulation in the wound 
site. Many lines of evidence suggest that MSCs produce 
several essential growth factors, including hepatocyte 
growth factor (HGF), transforming growth factor (TGF) and 
granulocyte-macrophage colony-stimulating factor (GM- 
CSF), as well as hematopoietic growth factors IL-6, IL-7, 
IL-8, IL-11, IL-12, IL-14, and stem cell factor (SCF) [41]. 
Lange et al. [45] showed long-term survival of mice after 
lethal irradiation, with fast hematopoietic recovery after 
exclusive transplantation of MSCs, without support of hem-
atopoietic stem cells (HSCs). In comparison to HSC-   
transplanted animals, MSC-transplanted animals display 
enhanced regenerative features, characterized by decreased 
proinflammatory cytokines, enhanced extracellular matrix 
(ECM) formation and adhesion properties and boosted an-
ti-inflammation, detoxification, cell cycle and anti-oxidative 
stress control [46]. 
Previous studies report that MSCs lack expression of 
MHC class II and most of the classical co-stimulatory mol-
ecules, such as CD80, CD86 and CD40 [47,48]. MSCs have 
been shown to regulate the activity in a range of effector 
cells involved in both innate and adaptive immunities. 
MSCs could inhibit up-regulation of CD1a, CD40, CD80, 
and CD86 during dendritic cell (DC) maturation. Different 
studies report that MSCs have an immunomodulatory effect 
and are able to suppress proliferation of T-lymphocytes in 
vitro [48–50]. MSCs can inhibit T-cell function, shift the 
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T-helper lymphocyte balance and induce T-cell apoptosis 
[51]. Di Nicola et al. [52] further identified that MSCs me-
diate their suppressive effect by suppression of T-cell pro-
liferation or through modulation of antigen-presenting cell 
phenotype and function. This immunosuppression has been 
shown to be mediated by cell-contact-dependent and 
-independent mechanisms, through the release of soluble 
factors. The interaction between MSCs and natural killer 
(NK) cells may contribute to the immunomodulatory effect 
of MSCs [53]. Crosstalk between MSCs and cells of the 
immune system leads to increased secretion of soluble im-
munomodulatory factors [54]. However, further research 
needs to be done to successfully identify the requirement of 
cell-to-cell contact. 
The therapeutic efficacy of MSCs anti-inflammatory 
properties has been established in a number of preclinical 
models including graft versus host disease, inflammatory 
bowel disease, sepsis and allergic airway disease [53–55]. 
Furthermore, radio protective gene therapy as a therapeutic 
paradigm holds tremendous promise for patients who un-
dergo radiotherapy with various types of malignancies. Ac-
cordingly, stem cell therapy using genetically modified 
MSCs may be an attractive and potential option for GI syn-
drome.  
The generation of ROS is considered as the main cause 
of ionizing radiation-induced cellular, tissue and organ tox-
icity. It not only contributes to apoptosis and functional 
changes of intestinal crypt cells, but also results in a com-
plex interplay of pathophysiological processes. These dele-
terious effects, including inflammatory responses, diarrhea, 
hematochezia and malabsorption, are seen clinically as 
acute small bowel reactions. To suppress the toxic effects of 
radiation, gene therapy approaches are being developed to 
deliver proteins that suppress ROS toxicity. Manganese 
superoxide dismutase (MnSOD) is the major antioxidant 
enzyme localized in the mitochondria, catalyzing the dis-
mutation of superoxide into oxygen and hydrogen peroxide, 
and protecting mitochondria against ROS [56]. Intraesoph-
ageal administration of MnSOD-plasmid/liposome 
(MnSOD-PL) reduces esophageal epithelial damage and 
improves migration of restorative bone marrow progenitors 
to the esophageal squamous epithelium. Niu et al. [57] 
demonstrate the efficacy of MnSOD-PL in suppressing ra-
diation-induced recombination in vivo. MnSOD has been 
shown to ameliorate radiation-induced injury through tar-
geted localization to the mitochondrial membrane. Gene 
therapy using MnSOD-PL protects against radiation-   
induced tissue damage and suppresses radiation-induced 
inflammation, suggesting that expression of the MnSOD 
transgene reduces levels of ROS [58]. Administration of the 
MnSOD transgene in liposomes/plasmid or adenovirus re-
duces both the acute and chronic toxicity of irradiation in 
the mouse model [59,60]. Overexpression of the MnSOD 
gene, through the use of either adenoviral or retroviral vec-
tors, has been shown to ameliorate radiation-induced inju- 
ries in the brain, lung, oral cavity mucosa and skin. More 
recently, our group has demonstrated that overexpression of 
human MnSOD in MSCs protects against tert-butyl hy-
droperoxide (t-BHP)-induced apoptosis in vitro [61]. Fur-
thermore, we showed that administration of MnSOD-MSCs 
extends the life span of irradiated mice. MSC migrates to 
the small intestine, encourages the repair of radiation-  
induced intestinal structural damage, and inhibits radia-
tion-induced apoptosis in a process involving the inhibition 
of cleaved caspase-3 activity [62]. These results indicate 
that gene therapy using MnSOD-PL protects against radia-
tion-induced tissue damage and suppresses radiation-   
induced inflammation, suggesting that expression of the 
MnSOD transgene reduces levels of ROS. 
All these findings suggest that MSCs have therapeutic 
potential in GI syndrome. Microenvironmental changes, 
induced by tissue injury, may play a key role in the homing 
and recruitment of circulating MSCs. MSCs have been 
shown to secrete massive amounts of molecules, including 
bioactive and ECM factors. Interestingly, the secretion of 
bioactive factors by MSCs is regulated in a manner closely 
associated with their growth and differentiation. These effects 
exhibit a common trophic mode of action: (i) inhibition of 
apoptosis and limitation of the local injury; (ii) inhibition of 
fibrosis or scarring at sites of damage; (iii) stimulation of 
mitosis of tissue-specific and endogenous stem cells.  
Based on the literature discussed herein, the mechanism 
of action for MSCs in GI syndrome is proposed as follows. 
MSCs migrate to irradiation exposed sites, where they pro-
duce vital biomolecules and antioxidants by the paracrine 
system. The MSCs then transdifferentiate to promote recon-
struction of the enteric microenvironment and modulate the 
enteric immunity, possibly to form intestinal functional 
cells.  
5  Prospects for future research 
MSCs are adult stem cells most commonly isolated from 
bone marrow that possess unique immunomodulatory and 
paracrine properties, which make them attractive for a wide 
range of diseases in regenerative medicine. Pioneer in vivo 
studies have mainly focused on their ability to engraft to the 
injured GI tract and promote structural and functional repair 
of damage tissues. The ability to efficiently transfer genes 
of interest into these cells would create a number of thera-
peutic opportunities. Together, these characteristics make 
MSCs an ideal candidate for treatment application in GI 
syndrome. Of the proposed mechanisms of action used by 
MSC, immunomodulation has been somewhat elucidated in 
vitro; however, data from preclinical transplant models re-
garding this are unclear. Furthermore, the optimal timing, 
dose and route of administration of MSCs remain to be elu-
cidated. In summary, preclinical studies still need to be 
performed for the safe use of MSCs in future clinical appli-
cations. 
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